Scholarlink

<p>Cutaneous immune-related adverse events caused by immune checkpoint inhibitors are among the earliest and most common adverse reactions during tumor immunotherapy, resulting in substantial physical and psychological distress for patients. In severe cases, delayed or non-standard treatment may lead to life-threatening complications. The clinical manifestations of cutaneous immune-related adverse events are diverse and complex; considerable uncertainty exists regarding their diagnosis and management, including whether to discontinue tumor immunotherapy. This consensus provides a systematic analysis, comprehensive evaluation, and recommendations on the classification, clinical presentation, and treatment of cutaneous immune-related adverse events, as well as guidance concerning whether tumor immunotherapy should be discontinued. Emphasis is placed on the fact that immune-related adverse events often affect multiple organs and systems. Therefore, clinical assessments should extend beyond cutaneous involvement to include potential complications affecting the heart, lungs, endocrine system, and digestive system.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Multi-disciplinary expert consensus on cutaneous adverse events caused by immune checkpoint inhibitors (2025)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月3日

查看全文
  • Yi Sun,
  • Junxia Huang,
  • Feifei Hu,
  • Ruyi Xue,
  • Xinxia Chang,
  • Leilei Cheng,
  • Yuehong Cui,
  • Jinjun Jiang,
  • Xiaomin Ou,
  • Danqi Deng,
  • Xiaoyu Li,
  • Yunsheng Liang,
  • Hong Liu,
  • Hai Long,
  • Xiaoyan Lv,
  • Jianjun Qiao,
  • Hui Tang,
  • Wenhui Wang,
  • Yumin Xia,
  • Chongmei Xin,
  • Ming Li,
  • Ji Yang

摘要

Cutaneous immune-related adverse events caused by immune checkpoint inhibitors are among the earliest and most common adverse reactions during tumor immunotherapy, resulting in substantial physical and psychological distress for patients. In severe cases, delayed or non-standard treatment may lead to life-threatening complications. The clinical manifestations of cutaneous immune-related adverse events are diverse and complex; considerable uncertainty exists regarding their diagnosis and management, including whether to discontinue tumor immunotherapy. This consensus provides a systematic analysis, comprehensive evaluation, and recommendations on the classification, clinical presentation, and treatment of cutaneous immune-related adverse events, as well as guidance concerning whether tumor immunotherapy should be discontinued. Emphasis is placed on the fact that immune-related adverse events often affect multiple organs and systems. Therefore, clinical assessments should extend beyond cutaneous involvement to include potential complications affecting the heart, lungs, endocrine system, and digestive system.